FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results